509079 Stock Overview
Manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Gufic Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹420.85 |
| 52 Week High | ₹501.10 |
| 52 Week Low | ₹278.00 |
| Beta | 0.80 |
| 11 Month Change | -3.22% |
| 3 Month Change | 15.76% |
| 1 Year Change | 41.72% |
| 33 Year Change | 125.72% |
| 5 Year Change | 533.33% |
| Change since IPO | 2,504.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 509079 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.9% | -3.1% | -3.4% |
| 1Y | 41.7% | 41.1% | 27.0% |
Return vs Industry: 509079 matched the Indian Pharmaceuticals industry which returned 41.1% over the past year.
Return vs Market: 509079 exceeded the Indian Market which returned 27% over the past year.
Price Volatility
| 509079 volatility | |
|---|---|
| 509079 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 509079 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 509079's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 1,491 | Pranav Choksi | www.gufic.com |
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments.
Gufic Biosciences Limited Fundamentals Summary
| 509079 fundamental statistics | |
|---|---|
| Market cap | ₹42.20b |
| Earnings (TTM) | ₹849.28m |
| Revenue (TTM) | ₹8.04b |
49.7x
P/E Ratio5.3x
P/S RatioIs 509079 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 509079 income statement (TTM) | |
|---|---|
| Revenue | ₹8.04b |
| Cost of Revenue | ₹3.84b |
| Gross Profit | ₹4.20b |
| Other Expenses | ₹3.35b |
| Earnings | ₹849.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.47 |
| Gross Margin | 52.28% |
| Net Profit Margin | 10.57% |
| Debt/Equity Ratio | 49.4% |
How did 509079 perform over the long term?
See historical performance and comparison